Establishment of therapeutic strategy for synchronous double lung cancers based on molecular analysis

我们对12例无淋巴结转移的同步双肺癌患者(同叶肺内转移6例，原发灶6例)进行了分子分析。然后，我们评估了经病理诊断的同步双肺癌患者(肺内转移(PM)：80例，原发：39例)和其他T3型肿瘤(230例)的临床结果。配对肿瘤的拷贝数变化(CNCS)符合率(CR)显示，转移组高于原发组(55.5%比19.6%，P=0.04)。病理诊断与分子分型一致10例(83%)。在本研究中采用的aCGH的病理学评估和分子评估似乎具有一致性。

We performed molecular analysis of 12 synchronous double lung cancer patients without lymph node metastasis (intrapulmonary metastasis in the same lobe (pm1): n=6, primary: n=6). We then evaluated the clinical outcomes of patients with pathologically diagnosed synchronous double lung cancers (intrapulmonary metastasis (pm): n=80, primary: n=39) and other T3 tumors (n=230). Examination of the concordance rate (CR) of the copy number changes (CNCs) for paired tumors showed that the metastasis group was larger than the primary group (55.5% vs. 19.6%, p=0.04). Pathological diagnosis and molecular classification were the same in 10 out of 12 cases (83%). Both pathological and molecular assessment using aCGH adapted in the current study appeared to have a consistency.